Skip to content
10-K

Annual Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-000426

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 11, 2026 207.03M sh
Gross Profit FY 2024 · Jan 31, 2024 $0
Gross Profit FY 2024 · Jan 31, 2023 −$3.33M
Cost Of Revenue FY 2024 · Jan 31, 2024 $0
Cost Of Revenue FY 2024 · Jan 31, 2023 $3.33M
Shares Diluted FY 2024 · Jan 31, 2023 206.52M sh
Operating Cash Flow FY 2024 · Jan 31, 2023 −$77.56K
Current Liabilities FY 2024 · Jan 31, 2023 $3.07M
Total Liabilities FY 2024 · Jan 31, 2023 $3.16M
Current Assets FY 2024 · Jan 31, 2023 $437.08K
Total Assets FY 2024 · Jan 31, 2023 $765.95K
Eps Diluted FY 2024 · Jan 31, 2023 −$0.02
Sga Expense FY 2024 · Jan 31, 2023 $844.84K
Net Income FY 2024 · Jan 31, 2023 −$4.16M
Operating Income FY 2024 · Jan 31, 2023 −$4.18M
Revenue FY 2024 · Jan 31, 2023 $0
Stockholders Equity FY 2024 · Jan 31, 2022 $1.58M